AbbVie said the FDA approved an antibody-drug conjugate (ADC) it obtained through its $10.1 billion buyout of ImmunoGen. The approval covers an ultra-rare but aggressive blood cancer indication, marking a milestone for the acquired ADC portfolio. The approval follows AbbVie’s strategy to bring late-stage and label-ready ADC assets into its hematology pipeline. The move also highlights how large pharma is continuing to harvest oncology ADC value from consolidation even as next-gen modalities compete for attention. For biotech and investors, the key point is label progression after M&A integration—turning acquisition deal terms into regulatory and commercial milestones rather than platform promises. The immediate market implication is how quickly AbbVie can translate approval into pricing discussions, launch execution, and potential sequencing with other hematology treatments.